Estados Unidos · Bolsa y Finanzas · CNBC

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Publicado por CNBC · Estados Unidos hace 1 h

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

Leer el artículo completo en CNBC Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbc.com)

También te puede interesar

Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline

E.E.O.C. Sues Harvard for Data on Diversity in Hiring Practices

Business Insider

15 US colleges now cost more than $100,000 a year. See the list, ranked by cost of attendance.

Open USD takes on Tether, Circle with a different stablecoin model that's 'building money'

The 'Gen Z stare' is telling us something important about today's economy

FedEx orders 2,000 electric trucks from Harbinger in $300M deal